loading
Phathom Pharmaceuticals Inc stock is traded at $11.91, with a volume of 1.99M. It is up +8.77% in the last 24 hours and up +50.76% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$10.95
Open:
$11
24h Volume:
1.99M
Relative Volume:
0.91
Market Cap:
$844.94M
Revenue:
-
Net Income/Loss:
$-297.11M
P/E Ratio:
-2.2948
EPS:
-5.19
Net Cash Flow:
$-216.95M
1W Performance:
+16.31%
1M Performance:
+50.76%
6M Performance:
+110.05%
1Y Performance:
-7.03%
1-Day Range:
Value
$10.96
$12.15
1-Week Range:
Value
$9.82
$12.15
52-Week Range:
Value
$2.21
$19.71

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name
Name
Phathom Pharmaceuticals Inc
Name
Phone
(877) 742-8466
Name
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Name
Employee
427
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PHAT's Discussions on Twitter

Compare PHAT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PHAT
Phathom Pharmaceuticals Inc
11.91 716.53M 0 -297.11M -216.95M -5.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-25 Initiated Cantor Fitzgerald Overweight
May-03-24 Initiated Stifel Buy
Jan-05-24 Reiterated Needham Buy
Aug-09-23 Initiated H.C. Wainwright Buy
May-11-23 Upgrade Evercore ISI In-line → Outperform
Mar-13-23 Initiated Craig Hallum Buy
Oct-21-22 Initiated Jefferies Buy
May-06-22 Downgrade Evercore ISI Outperform → In-line
May-12-21 Upgrade Goldman Sell → Neutral
Feb-17-21 Initiated BMO Capital Markets Outperform
Feb-02-21 Initiated Guggenheim Buy
Jun-26-20 Downgrade Goldman Neutral → Sell
Nov-20-19 Initiated Evercore ISI Outperform
Nov-19-19 Initiated Goldman Neutral
Nov-19-19 Initiated Jefferies Buy
Nov-19-19 Initiated Needham Buy
View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

pulisher
Aug 20, 2025

RSI and MACD Indicate Shift in Phathom Pharmaceuticals Inc. SentimentJuly 2025 Outlook & Free Real-Time Volume Trigger Notifications - beatles.ru

Aug 20, 2025
pulisher
Aug 20, 2025

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know - MSN

Aug 20, 2025
pulisher
Aug 20, 2025

Phathom Says No Ownership Changes in Frazier Life Sciences Regulatory Filing - MarketScreener

Aug 20, 2025
pulisher
Aug 20, 2025

Phathom Pharmaceuticals clarifies no reduction in Frazier ownership - Investing.com

Aug 20, 2025
pulisher
Aug 20, 2025

Phathom Pharmaceuticals Clarifies That There Is No - GlobeNewswire

Aug 20, 2025
pulisher
Aug 20, 2025

Administrative 13D Filing Update: Phathom Pharmaceuticals Confirms No Reduction in Major Shareholder Stakes - Stock Titan

Aug 20, 2025
pulisher
Aug 17, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Soars 29% But It's A Story Of Risk Vs Reward - 富途牛牛

Aug 17, 2025
pulisher
Aug 17, 2025

Published on: 2025-08-17 07:30:13 - metal.it

Aug 17, 2025
pulisher
Aug 15, 2025

Insider Sales At Phathom Pharmaceuticals Landed A Good Price - simplywall.st

Aug 15, 2025
pulisher
Aug 14, 2025

Quant Models Detect Momentum Reversal in Phathom Pharmaceuticals Inc.Analyst Upgrade & Smart Swing Trading Alerts - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 14, 2025

Can Phathom Pharmaceuticals Inc. Bounce Back From Weekly LowJuly 2025 Sentiment & Low Volatility Stock Recommendations - beatles.ru

Aug 14, 2025
pulisher
Aug 13, 2025

Phathom Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks

Aug 13, 2025
pulisher
Aug 12, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Shareholders Are up 19% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛

Aug 12, 2025
pulisher
Aug 12, 2025

Chartists Watching For Breakout in Phathom Pharmaceuticals Inc.Price Movement Prediction Analysis Review - beatles.ru

Aug 12, 2025
pulisher
Aug 12, 2025

Phathom Pharmaceuticals Reports Strong Q2 Growth - TipRanks

Aug 12, 2025
pulisher
Aug 11, 2025

Bullish Candlestick Pattern Forms in Phathom Pharmaceuticals Inc.Growth Focused Entry Plan Suggestions Issued - metal.it

Aug 11, 2025
pulisher
Aug 09, 2025

Phathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

Phathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance

Aug 09, 2025
pulisher
Aug 09, 2025

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 09, 2025
pulisher
Aug 09, 2025

Phathom Pharmaceuticals (PHAT) Gets a Buy from H.C. Wainwright - The Globe and Mail

Aug 09, 2025
pulisher
Aug 08, 2025

Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $17 - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $17 to $28 - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

Phathom 2025 Q2 Earnings Net Loss Narrows 17.1% - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Phathom Pharmaceuticals Inc (PHAT) Q2 2025 Earnings Call Highlig - GuruFocus

Aug 08, 2025
pulisher
Aug 07, 2025

Phathom Pharmaceuticals Q2 2025: Unpacking Contradictions in Growth Strategies and Market Focus - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Phathom Pharmaceuticals Stock (PHAT) Opinions on Q2 2025 Earnings Report - Quiver Quantitative

Aug 07, 2025
pulisher
Aug 07, 2025

Phathom Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beat - Investing.com Canada

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings call transcript: Phathom Pharmaceuticals Q2 2025 beats revenue expectations - Investing.com Australia

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings call transcript: Phathom Pharmaceuticals Q2 2025 beats revenue expectations By Investing.com - Investing.com South Africa

Aug 07, 2025
pulisher
Aug 07, 2025

Phathom Pharmaceuticals shares rise 11.41% intraday after reporting Q2 revenue beating estimates. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Phathom Pharmaceuticals (PHAT) Q2 Earnings: Revenue Surpasses Es - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

Phathom Pharmaceuticals Q2 2025 Financial Results - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Phathom Pharmaceuticals' Strategic Restructuring and Market Position: A Pathway to Long-Term Value Creation in a Capital-Constrained Biopharma Landscape - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

Phathom Pharmaceuticals Inc (PHAT) Q2 2025 Earnings Call Highlights: Revenue Surge and ... By GuruFocus - Investing.com Canada

Aug 07, 2025
pulisher
Aug 04, 2025

Published on: 2025-08-04 08:41:19 - metal.it

Aug 04, 2025
pulisher
Aug 03, 2025

Does Phathom Pharmaceuticals Inc. stock perform well during market downturnsOutstanding trading profits - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Phathom Pharmaceuticals Inc. a growth stock or a value stockBuild a portfolio that withstands market volatility - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is it the right time to buy Phathom Pharmaceuticals Inc. stockDiscover undervalued stocks before they soar - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Phathom Pharmaceuticals Inc. generate profit in a changing economySkyrocketing investment returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Should I hold or sell Phathom Pharmaceuticals Inc. stock in 2025Achieve impressive returns with smart timing - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How many analysts rate Phathom Pharmaceuticals Inc. as a “Buy”Unlock exclusive stock market insights - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

When is Phathom Pharmaceuticals Inc. stock expected to show significant growthInvest smarter with data-backed trading alerts - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What is the dividend policy of Phathom Pharmaceuticals Inc. stockBuild wealth steadily with proven strategies - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What catalysts could drive Phathom Pharmaceuticals Inc. stock higher in 2025Free Stock Market Real-Time Monitoring - Jammu Links News

Aug 02, 2025
pulisher
Aug 01, 2025

Several Insiders Invested In Phathom Pharmaceuticals Flagging Positive News - 富途牛牛

Aug 01, 2025
pulisher
Aug 01, 2025

Published on: 2025-08-01 16:17:13 - metal.it

Aug 01, 2025
pulisher
Jul 28, 2025

Elliott Wave Theory Predicts Pullback in Phathom Pharmaceuticals Inc.Low Risk Picks for Daily Trading Released - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Phathom Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire

Jul 28, 2025

Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Phathom Pharmaceuticals Inc Stock (PHAT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Topper James N
Director
May 21 '25
Buy
3.86
3,780
14,609
59,403
Topper James N
Director
May 14 '25
Buy
3.32
6,300
20,919
55,623
Topper James N
Director
May 13 '25
Buy
3.16
1,120
3,543
49,323
Topper James N
Director
May 09 '25
Buy
3.22
35,602
114,616
35,602
Topper James N
Director
May 12 '25
Buy
3.04
12,601
38,301
48,203
Parikh Asit
Director
May 06 '25
Buy
2.60
5,000
13,000
90,500
Parikh Asit
Director
May 07 '25
Buy
2.40
5,000
11,984
95,500
Henderson Molly
CFO and CBO
Apr 07 '25
Sale
4.55
3,678
16,740
89,868
Parikh Asit
Director
Sep 10 '24
Option Exercise
11.72
7,500
87,900
93,000
Parikh Asit
Director
Mar 13 '25
Buy
4.42
10,000
44,200
85,500
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):